Furthermore, the use of organoid tissue from the Akt-FRET biosensor mouse crossed with precise genetically defined tumor mouse models can be used as an ongoing efficient and preclinical screening tool of specific genetic contexts to mimic genetic aberration and help optimize targeted therapeutic combinations from distinct genetic backgrounds. This evidence concerns the gene AKT1 and neoplasm.